SNTI

Senti Biosciences Holdings, Inc.

• TipRanks·20h ago

  Senti Biosciences Details New Direct Financial Obligation

• PUBT·21h ago

  Senti Biosciences unit issues USD 10 million senior secured convertible notes to Celadon Partners SPV 24

• TipRanks·05/17 16:40

  Analysts Conflicted on These Healthcare Names: Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx Se (ARGX)

• TipRanks·05/16 06:00

  Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure

• Dow Jones·05/15 12:27

  Senti Biosciences Is Maintained at Buy by Chardan Capital

• Dow Jones·05/15 12:27

  Senti Biosciences Price Target Raised to $12.00/Share From $11.00 by Chardan Capital

• Benzinga·05/15 12:17

  Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

• TipRanks·05/15 10:25

  Analyst Maintains Buy on Senti Biosciences, Keeps $12 Price Target on Strengthened Clinical, Regulatory, and Financial Position

• PUBT·05/14 20:22

  Senti Biosciences Q1 FY26 net loss narrows to $4.22 million; revenue rises to $16,000

• Seeking Alpha·05/14 18:25

  Senti Biosciences GAAP EPS of -$0.14, revenue of $0.01M

• TipRanks·05/14 13:42

  Senti Bio completes Type B RMAT meeting with FDA on SENTI-202

• TipRanks·05/14 13:38

  Senti Bio reports Q1 EPS (14c), consensus (36c)

• TipRanks·05/14 13:18

  Senti Biosciences Advances SENTI-202 With New FDA Support

• Reuters·05/14 12:54

  Senti Biosciences Q1 net loss narrows on cost reduction

• Benzinga·05/14 12:46

  Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K